Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
100 
Let's personalize your content